A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: Pain
In brief
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of intravenously administered VX-993 at different doses in healthy participants.
Key facts
- Study ID
- NCT06394167
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 88
- Starts
- 2024-05-09
- Expected to finish
- 2025-02-18
- Last updated by the study team
- 2025-03-20
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- ICON Lenexa — Lenexa, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.